You are here: Industry Insights > Emmaus Life Sciences

News List

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine prnasia
October 13, 2021
Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos Medicine, Inc.
FDA Approves Updated Label for Endari americanpharmaceuticalreview
November 12, 2020
Emmaus Life Sciences has announced revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.
Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region biospectrumasia
December 24, 2019
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
Emmaus Life Sciences Completes Merger americanpharmaceuticalreview
July 19, 2019
Emmaus Life Sciences and MYnd Analytics announced they have completed the previously announced merger transaction, following stockholder approval by both companies on July 9.
Emmaus Life Sciences Announces Study Protocol for Pharmaceutical-grade L-glutamine americanpharmaceuticalreview
June 26, 2019
Emmaus Life Sciences has announced the use of its pharmaceutical-grade L-glutamine (PGLG) in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.